Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SNG-1153 by Shenogen Pharma Group for Hepatocellular Carcinoma: Likelihood of Approval
SNG-1153 is under clinical development by Shenogen Pharma Group and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...